Phaarmasia Limited (BOM:523620)
98.74
-0.49 (-0.49%)
At close: Jul 6, 2026
Phaarmasia Revenue
In the fiscal year ending March 31, 2026, Phaarmasia had annual revenue of 472.08M INR with 93.72% growth. Phaarmasia had revenue of 77.32M in the quarter ending March 31, 2026, with 42.39% growth.
Revenue
472.08M
Revenue Growth
+93.72%
P/S Ratio
1.43
Revenue / Employee
13.11M
Employees
36
Market Cap
677.37M
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2026 | 472.08M | 228.39M | 93.72% |
| Mar 31, 2025 | 243.69M | -62.25M | -20.35% |
| Mar 31, 2024 | 305.93M | 31.04M | 11.29% |
| Mar 31, 2023 | 274.90M | 102.74M | 59.68% |
| Mar 31, 2022 | 172.16M | -31.79M | -15.59% |
| Mar 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Mangalam Drugs & Organics | 2.32B |
| Makers Laboratories | 1.41B |
| Godavari Drugs | 1.07B |
| Mercury Laboratories | 759.37M |
| Shelter Pharma | 731.34M |
| Source Natural Foods and Herbal Supplements | 703.77M |
| Onyx Biotec | 694.69M |
| Amwill Health Care | 454.92M |